论文部分内容阅读
最近,张江高科参股企业上海复旦张江生物医药股份有限公司（复旦张江）以配售方 式在香港联交所创业板市场发行19800万股H股,融资约1.58亿港元。本次新 股发行后,该公司随即在香港创业板市场上市。香港创业板似乎正在成为国内民营企业海外上市的福地。据香港方面的媒体报道,今年上半年联交所新上市的企业中有三分之一以上是内地民企,计划在今明两年上市的国内民企至少有50家;而目前处于辅导期,预计将于明后两年上市的则有300多家。国内企业尤其是民营企业有可能成为未来香港资本市场的主流板块。
Recently, Zhangjiang Hi-Tech joint-stock company Shanghai Fudan-Zhangjiang Biological Medicine Co., Ltd. (Fudan-Zhangjiang) issued a placing of 198 million H shares on the GEM of Hong Kong Stock Exchange with a financing of about HK $ 158 million. After the IPO, the company was listed on the Hong Kong GEM. Hong Kong GEM seems to be becoming a blessed land for overseas listing of private enterprises. According to Hong Kong media reports, more than one-third of newly listed companies in the first half of this year are mainland private enterprises. At least 50 private domestic enterprises are planning to list in the next two years. Currently, they are under counseling and are expected to In the next two years there are more than 300 listed. Domestic enterprises, especially private ones, may become the mainstream of the Hong Kong capital market in the future.